HOME >> MEDICINE >> NEWS
Positive results for ACRUX's lead product in US Phase 3 trial

Acrux (ASX: ACR), the pharmaceutical company with unique technology for delivering drugs through the skin, today announced positive results in a US Phase 3 clinical trial of Evamist, its daily skin spray for prevention of symptoms associated with menopause. The trial was conducted by its US commercial partner VIVUS Inc. (NASDAQ: VVUS), which will now proceed to file a marketing application with the US Food and Drug Administration (FDA) in the second half of 2006.

Evamist is the most advanced commercial application of Acrux's patented delivery technology; if the FDA approves VIVUS' marketing application, Acrux's first product could be available to women in the USA in the second half of 2007. Several other products that use the same delivery technology are following close behind. The positive result of this Phase 3 trial is therefore a pivotal milestone for each of these products.

The Phase 3 trial assessed the safety and efficacy of Evamist for the treatment of hot flushes in menopausal women. The trial was a 12-week study of 457 menopausal women, conducted under a Special Protocol Assessment (SPA) from the FDA. Results showed that the most effective Evamist dose decreased the number of hot flushes by 78%. The reduction in frequency and severity of moderate to severe hot flushes was statistically significant compared with placebo for all three doses of Evamist evaluated.

Importantly, application site irritation was less than 1% and was mild in nature. The results from the trial will be discussed by VIVUS at an Analyst Day in New York on 18 May 2006.

"We believe these positive trial results along with this novel patient-preferred transdermal delivery system will establish Evamist as a superior estrogen therapy for the treatment of menopausal symptoms," stated Leland Wilson, president and chief executive officer for VIVUS. "We have worked diligently toward the development of this unique and easy-to-use product, and we are thrilled with
'"/>

Contact: Igor Gonda
61-38-379-0100
Research Australia
9-May-2006


Page: 1 2

Related medicine news :

1. Positive results more likely from industry-funded breast cancer trials
2. M. D. Anderson reports first drug activity in T315I-Positive CML, ALL and JAK-2-Positive MPD
3. Positive parenting helps encourage healthy sun habits in children
4. Positive outcome of Medicare drug benefit
5. Positive study results for methylphenidate transdermal system
6. Positive study results for methylphenidate transdermal system
7. Stem cell transplantation procedure results in long-term survival for amyloidosis patients
8. GSKs Pazopanib shows positive results in patients with advanced renal cell carcinoma
9. GSKs Pazopanib shows positive results in patients with advanced RCC and ovarian cancer
10. Targeted, oral agent Enzastaurin shows favorable results
11. Childhood obesity intervention shows promising results

Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Positive results for ACRUX lead product Phase trial

(Date:11/24/2014)... The Holiday Inn Westbury - Long Island ... Association to donate various items consisting of practical, ... such items.The Association's program is aimed toward helping over ... nursing homes, assisted living facilities and nursing homes. The ... of seniors throughout the Long Island area. The Holiday ...
(Date:11/24/2014)... and Philadelphia, PA (PRWEB) November 24, 2014 ... of care coordination and disease management services to ... chosen to implement Essetteā€™s Medical Management software suite. ... Essette SaaS platform in a program to reduce ... suite includes Population Health Management, Care Management, Utilization ...
(Date:11/23/2014)... iFitDress.com, a well-known wedding dress manufacturer, has unveiled its ... They are now offered at deeply discounted prices, up to ... to Dec. 15. The main purpose of the promotion is ... quality items are ideal options for ladies who are eager ... All its new mint cocktail dresses are very beautiful; they ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 Nearly ... heart attacks, strokes, deep vein thrombosis and other ... a federal multidistrict litigation (MDL) underway in the ... , Court documents updated on November 17th ... (JPML) show the filing of 259 lawsuits against ...
(Date:11/23/2014)... (PRWEB) November 23, 2014 To show thanks ... its new collection of white evening dresses for ... online workers 24/7. , iFitDress.com is a distinguished dress manufacturer, ... and supported by worldwide customers for a very long time. ... place where a customer will be able to buy not ...
Breaking Medicine News(10 mins):Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 2Health News:The Holiday Inn Westbury - Long Island gives back to the local Long Island community, and also goes beyond borders to assist those in need during the 2014 Holiday Season 3Health News:ReAdmission Solutions, LLC Selects Essette 2Health News:Trendy Long Black Evening Gowns Now Provided By iFitDress.com 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 2Health News:Testosterone Lawsuits Approach 260 in Illinois Federal Court Litigation, Bernstein Liebhard LLP Reports 3Health News:iFitDress.com: Wonderful White Evening Dresses Now Available 2
(Date:11/24/2014)... Nov. 24, 2014  Surgical Theater, LLC, announced today ... 24 th opening of Europe,s ... Nazionale "C. Besta." The SuRgical Planner (SRP) and the ... the event for their 3D navigation and augmented reality ... Bederson , Professor and Chair, Department of Neurosurgery at ...
(Date:11/24/2014)... 24, 2014  Pifflers United Chronic and Invisible ... release of results of a study of ActiPatch®, ... self-management of fibromyalgia pain. The results demonstrated that ... very significant clinically meaningful pain reduction can be ... with fibromyalgia used ActiPatch® for 7 days and ...
(Date:11/22/2014)...  Sprout Pharmaceuticals today announced positive preliminary results from a ... flibanserin up to 200 mg at bedtime had no next-day ... 20 th Annual Fall Scientific Meeting of the Sexual ... Miami . The Phase 1 ... Letter and the Formal Dispute Resolution that was filed in ...
Breaking Medicine Technology:Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 2Surgical Theater's Technology to be Showcased at the Opening of the Besta NeuroSim Center in Milan, Italy 3Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 2Pifflers United - "Supporting Anyone Living With Chronic/Invisible Illness" Reports ActiPatch Bioelectronic Therapy Relieves Chronic Pain In Fibromyalgia 3Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 2Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 3
Cached News: